Skip to main content
Caplight Logo









Paradox Immunotherapeutics

Paradox Immunotherapeutics

Private
TorontoHealthcare & Life Scienceshttps://www.paradoximmuno.com/

Last Round

Seed

Feb 25, 2025

Total Funding Raised

$10M

Company Overview

Paradox Immunotherapeutics is a biotechnology company developing monoclonal antibody therapies for the treatment of rare protein misfolding diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

monoclonal antibodymAbdrug discoveryamyloidosisprotein misfoldingprecision medicinebiotechin-silico drug designcomputational biologytherapeutic antibodyAI drug discoveryrare disease treatmentstructure-based designbiotech startupdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Paradox Immunotherapeutics Comparables

Compare Paradox Immunotherapeutics with similar companies based on industry and business-model similarity.

Paradox Immunotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Attralus
78%
AstraZeneca
73%
Prothena Corporation plc
72%

Paradox Immunotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 25, 2025

Key People

Founding team and executive leadership

Natalie J. Galant

Chief Executive Officer, Co-Founder

Founding Team

Paradox Immunotherapeutics Investors

Notable investors and investment history

Paradox Immunotherapeutics investors
InvestorRounds
SymBiosis Capital ManagementSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 25, 2025

    $10M raised in early funding.

  • Feb 25, 2025

    Selected for the Springboard Enterprises Life Sciences Program.

Paradox Immunotherapeutics Filings

Explore SEC and related filing metadata, where available.

Paradox Immunotherapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Paradox Immunotherapeutics's valuation, stock price, and market status.

Is Paradox Immunotherapeutics a public or private company?

Paradox Immunotherapeutics is a private company.

What is the current stock price of Paradox Immunotherapeutics?

Paradox Immunotherapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Paradox Immunotherapeutics worth (valuation)?

Valuation information for Paradox Immunotherapeutics is not publicly available.

Can I buy Paradox Immunotherapeutics stock?

Paradox Immunotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Paradox Immunotherapeutics's last funding round?

Paradox Immunotherapeutics's most recent funding round was Early Funding on February 25, 2025.

Who are the main investors in Paradox Immunotherapeutics?

Key investors in Paradox Immunotherapeutics include SymBiosis Capital Management.

Will Paradox Immunotherapeutics IPO soon?

No public IPO plans have been announced for Paradox Immunotherapeutics.

How can I track Paradox Immunotherapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Paradox Immunotherapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersToronto
Employee Range9
Year Founded2019
Last FundingFeb 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?